Evidence map›Paper›PMID 37306938›Full record

Trial reportInflammopharmacology2023

Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study.

Kai Zhang, Xiaoyan Miao, Liqiang Jiang, Shubei Cui, Zhenwu Liu, Zhiyun Wang

Abstract readRandomized Controlled TrialMulticenter StudyEquivalence Trial
PubMed Publisher
In one paragraph

Trial report in Inflammopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Imrecoxib: Advances in Pharmacology and Therapeutics.Drug design, development and therapy · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kai ZhangDepartment of Orthopedics, Handan Central Hospital, No. 59 Congtai North Road, Handan, 056000, China.
Xiaoyan MiaoDepartment of General Surgery, Affiliated Hospital of Hebei Engineering University, Handan, 056002, China.
Liqiang JiangDepartment of Orthopedics, Handan Central Hospital, No. 59 Congtai North Road, Handan, 056000, China.
Shubei CuiDepartment of Orthopedics, Handan Central Hospital, No. 59 Congtai North Road, Handan, 056000, China.
Zhenwu LiuDepartment of Orthopedics, Handan Central Hospital, No. 59 Congtai North Road, Handan, 056000, China.
Zhiyun WangDepartment of Orthopedics, Handan Central Hospital, No. 59 Congtai North Road, Handan, 056000, China. zhi86413926@163.com.ORCID http://orcid.org/0009-0005-6387-8763
Handan College · CNHebei University of Engineering · CN

Funding

2019 Municipal Science and Technology Special Plan of Handan Municipal Science and Technology Bureau 19422083011-9
6 · The paper itself

Abstract

backgroundImrecoxib, a novel cyclooxygenase-2 inhibitor, possesses a certain postoperative analgesic effect for several orthopedic surgeries. This multi-center, randomized, controlled, non-inferiority study intended to investigate the postoperative analgesic efficacy and safety profile of imrecoxib (versus celecoxib) in hip osteoarthritis patients undergoing total hip arthroplasty (THA).

methods156 hip osteoarthritis patients planned for THA were randomized into imrecoxib (N = 78) and celecoxib (N = 78) groups. Patients were orally administrated with imrecoxib or celecoxib 200 mg at 2 h (h) after THA, 200 mg every 12 h to day (D)3, and 200 mg every 24 h to D7; additionally, each patient received patient-controlled analgesia (PCA) for 2 days.

resultsResting pain visual analogue scale (VAS) score at 6 h, 12 h, D1, D2, D3, and D7 post THA was not varied between imrecoxib and celecoxib groups (all P > 0.050), neither was moving pain VAS score (all P > 0.050). Importantly, the upper of 95% confidence interval of pain VAS score margin between imrecoxib and celecoxib groups was within the non-inferiority threshold (Δ = 1.0), indicating the fact that non-inferiority was established. The additional and total consumption of PCA was not varied between imrecoxib and celecoxib groups (both P > 0.050). Also, no difference was seen in Harris hip score, European Quality of Life 5-Dimensions (EQ-5D) total and VAS scores at month (M)1, M3 between the two groups (all P > 0.050). Besides, the incidences of all adverse events were not different between imrecoxib and celecoxib groups (all P > 0.050).

conclusionImrecoxib is non-inferior to celecoxib for postoperative analgesia in hip osteoarthritis patients undergoing THA.

Indexed as

Arthroplasty, Replacement, HipOsteoarthritis, HipAnalgesicsCelecoxibCyclooxygenase 2 InhibitorsDouble-Blind MethodHumansPostoperative PainPyrrolesQuality of LifeSulfidesAnalgesicsCelecoxibCyclooxygenase 2 InhibitorsImrecoxibPyrrolesSulfidesCelecoxibImrecoxibPostoperative analgesiaSafetyTotal hip arthroplasty

Identifiers

PMID37306938
OpenAlexW4380264191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.